Mecasermin
FDA-approved lab-made human IGF-1 for severe primary IGF-1 deficiency (Increlex).
Ref $ —reference only
MecaserminFDA-approvedWhat it's for
FDA-approved lab-made human IGF-1 for severe primary IGF-1 deficiency (Increlex).
What it's for
Mecasermin is recombinant human insulin-like growth factor-1. It treats growth failure in children with severe primary IGF-1 deficiency or with growth hormone-gene deletion developing neutralizing antibodies to growth hormone, per label.
What it does for the body
It treats growth failure in children with severe primary IGF-1 deficiency or with growth hormone-gene deletion developing neutralizing antibodies to growth hormone, per label. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
IGF-1 receptors (lock-and-key landing spots on cells) activation mediates many anabolic/growth effects downstream of growth hormone. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Mecasermin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Hormones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Mecasermin — FDA.gov search
- ClinicalTrials.gov search: Mecasermin — U.S. clinical trials registry
- Drugs@FDA search: Mecasermin — FDA drug database (if approved)
- PubMed search: Mecasermin — NCBI PubMed
- PubMed Central search: Mecasermin — NCBI PMC
Reference
No ref on file.